Recherches alternatives:
eur acad » eur ace (Recherche élargie)
nur acar » nuran acar (Recherche élargie), nuray acar (Recherche élargie), nur akmar (Recherche élargie)
Résultat(s) 1 - 20 résultats de 492 pour la requête 'j ((eur acad) OR (((nur acar) OR ((nutrsan OR nutrian) acar)))) dermatol (venereol OR venereas)*', Temps de recherche: 3,09s Affiner les résultats
Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study
COVID‐19 and its implications for Dermatology and Venereology

The skin in the era of coronavirus pandemic
Dermato‐venereology in the year of coronavirus – Hot topics in research and patient care

Impact of the COVID‐19 pandemic on inpatient dermatology: a multicentre study from Hubei, China
Autoantibodies in Covid‐19 – a model for viral induced autoimmunity

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice
Acro‐ischaemia and COVID‐19 infection: clinical and histopathological features

Penile ischaemia secondary to COVID‐19: why should the dermatologist be concerned?
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry

Efficacy of hydrogel patches in preventing facial skin damage caused by mask compression in fighting against coronavirus disease 2019: a short‐term, self‐controlled study
Measurement of Tanning Dependence

Incidence and prognosis of COVID‐19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study
Occupational skin disease during the COVID‐19 pandemic, as captured in a Dermatology staff clinic in the United Kingdom

Concerns and perceptions of patients with psoriatic disease during the COVID‐19 pandemic: results from a two‐wave survey by the National Psoriasis Foundation
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Outils de recherche: S'abonner aux flux RSS — Envoyer cette recherche par courriel — Enregistrer la recherche